Vigil Neuroscience Inc (VIGL)
3.95
-0.06
(-1.37%)
USD |
NASDAQ |
Jul 03, 16:00
Vigil Neuroscience Research and Development Expense (Annual): 60.93M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 60.93M |
| December 31, 2022 | 47.44M |
| Date | Value |
|---|---|
| December 31, 2021 | 32.33M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
32.33M
Minimum
2021
60.93M
Maximum
2023
46.90M
Average
47.44M
Median
2022
Research and Development Expense (Annual) Benchmarks
| Assure Holdings Corp | -- |
| Tonix Pharmaceuticals Holding Corp | 86.66M |
| Savara Inc | 44.26M |
| TG Therapeutics Inc | 76.19M |
| scPharmaceuticals Inc | 11.81M |